Boehringer's brigimadlin trial in biliary and pancreatic cancer finishes without posted results
Brightline-2 completed its Phase 2 test of brigimadlin in MDM2-amplified biliary, pancreatic, lung and bladder tumors, but the objective-response data that will determine its next step have not posted.
Executive Summary
- A Phase 2 trial testing Boehringer Ingelheim's oral MDM2 inhibitor brigimadlin in four hard-to-treat cancer types has finished enrollment and follow-up, but the tumor-response data that the study was designed to generate have not yet been made public.
- The trial selected patients by a specific tumor biology, MDM2 amplification paired with normal TP53, testing whether targeting that pathway can produce responses in biliary tract, pancreatic, lung and bladder cancers that have exhausted standard options.
- No MDM2 inhibitor has completed a trial in biliary tract cancer before this one, and Boehringer's own MDM2 franchise is still mid-development everywhere else it has been tested, so this readout will be an early data point for the mechanism in tumors generally, not a comparison against an established rival.
- Enrollment landed within one patient of its target and the primary completion date moved several times before locking in, patterns that reflect ordinary trial administration rather than a program in distress.
The trial and its purpose
Brightline-2 enrolled patients with locally advanced or metastatic biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, lung adenocarcinoma, or urothelial bladder cancer whose tumors carried MDM2 amplification alongside wild-type TP53, and who had exhausted standard treatment options. Patients took brigimadlin, an oral small molecule that blocks the MDM2-p53 interaction, as a tablet once every three weeks. The single-arm, open-label study's primary endpoint was objective response, the share of patients whose tumors shrank enough to count as a complete or partial response by RECIST criteria. Secondary endpoints included disease control, duration of response, progression-free and overall survival, and treatment-related adverse events leading to discontinuation. NCT05512377Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or BladderNCT05512377
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Where it stands
The trial's primary completion date, originally targeted for February 2025, moved five times over its run before settling at September 25, 2025, when the registry recorded it as completed. Enrollment ended at 99 patients, essentially matching the trial's target after climbing as high as 155 during recruitment and being scaled back as cohorts filled. The registry briefly flagged the trial as terminated in May 2026 before reverting to completed status in July 2026, an oscillation that reads as a registry correction rather than a change in the trial's clinical course, though the underlying cause is not established. NCT05512377Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or BladderNCT05512377
What the data will show
No results have posted to ClinicalTrials.gov for this trial. The objective-response rate, once reported, will indicate whether MDM2 inhibition produces tumor shrinkage in this biomarker-defined population, and whether the effect differs across the four tumor types the trial pooled together. Because the design is single-arm and open-label, with no comparator, the readout will be hypothesis-generating rather than a controlled comparison against existing therapy.
The competitive field
MDM2 inhibitors have not yet demonstrated a completed, positive result in biliary tract adenocarcinoma; the only prior trial to pair this target with this indication was terminated. Boehringer's own brigimadlin program has since moved into a Phase 3 trial in dedifferentiated liposarcoma and a long-term extension study for patients from earlier brigimadlin trials, alongside peer MDM2 inhibitors from Kartos Therapeutics (navtemadlin, Phase 3 in myelofibrosis) and Rain Oncology (milademetan, Phase 3 in dedifferentiated liposarcoma), none of which have reported activity in biliary, pancreatic, lung or bladder cancer. Given that no MDM2 inhibitor has an established track record in tumors of this kind, a response rate that clears a level meaningfully above what would be expected from disease biology alone, and that holds up across more than one of the four cohorts, would be the finding that carries this mechanism forward in gastrointestinal and thoracic cancers.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.